title: Uricosuric effect of irtemazole in hyperuricemic patients without and with renal insufficiency.
abstract: A single oral dose of 50 mg irtemazole exhibited a clear cut uricosuric effect in five patients with hyperuricemia and normal renal function. The average maximal decrease of plasma uric acid was 46.1% compared to the initial value; it was reached between 6 h and 12 h after drug administration. Extent and course of plasma uric acid showed no differences between normouricemic (5) and hyperuricemic subjects. In four patients suffering from hyperuricemia and renal insufficiency only a minor effect of irtemazole was seen. The average maximal decrease of plasma uric acid reached 12.8% compared to the initial value. It occurred between 8 h and 12 h after drug ingestion. In both normouricemic and hyperuricemic subjects irtemazole acts more quickly than benzbromarone and probenecid. The duration of its uricosuric effect is shorter. Like benzbromarone, irtemazole exhibits only a minor effect in patients with reduced creatinine clearance.
authors.affiliation: Medizinische Poliklinik, Universität München.
authors.forename: I
authors.initials: I
authors.lastname: Kamilli
authors.forename: U
authors.initials: U
authors.lastname: Gresser
authors.forename: T
authors.initials: T
authors.lastname: Pellkofer
authors.forename: W
authors.initials: W
authors.lastname: Löffler
authors.forename: N
authors.initials: N
authors.lastname: Zöllner
mesh_terms: D000328:Adult; D000368:Aged; D001562:Benzimidazoles / Q000627:therapeutic use*; D005260:Female; D006073:Gout / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood*; D014528:Uricosuric Agents / Q000627:therapeutic use*
chemical_list: D001562:Benzimidazoles; D014528:Uricosuric Agents; D014527:Uric Acid; C060889:irtemazole